The MiniMed 780G automated insulin delivery (AID) system significantly improved time in range (TIR) and HbA1c compared to manual insulin pump therapy in children aged 2–6 years.
Safety profile was acceptable, with no severe hypoglycaemia and a single diabetic ketoacidosis event unrelated to device malfunction.
The LENNY trial supports early adoption of AID to potentially prevent long-term diabetes complications in young children.
